Randomized, Open-Label, Active Controlled, Two-Period Crossover Study To Evaluate Relative Efficacy And Safety of Investigational Captisol-Enabled Budesonide Inhalation Solution (CBIS) Delivered via eFlow Nebuliser and Conventional Budesonide Inhalation Suspension (Pulmicort Respules) Delivered via LC Plus Jet Nebuliser in Adult Patients with Mild To Moderate Persistent Asthma.
Phase of Trial: Phase II
Latest Information Update: 28 Jul 2017
At a glance
- Drugs Budesonide (Primary)
- Indications Asthma
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors Verus Pharmaceuticals
- 28 Jul 2017 Status changed from recruiting to completed (Global end Date:22-02-2007).
- 21 Jul 2011 New trial record